{"entity":{"id":"idea-fund-pay-for-cure-annuities","kind":"idea","name":"Outcome-based annuity payments for potentially curative one-time therapies","aka":[],"tldr":"Instead of paying hundreds of thousands up front for a CAR-T or gene therapy, the health system would pay in yearly instalments that stop if the cancer comes back, so companies are paid for cures, not attempts.","summary":"Outcome-based annuities, already used for some gene therapies (for example spinal muscular atrophy and haemophilia contracts in Europe), applied systematically to cell therapies, bispecifics with curative potential and future one-time oncology treatments: payment spread over five years, each instalment contingent on the patient remaining in remission by pre-agreed criteria (imaging, MRD negativity). Payers gain risk-sharing; manufacturers gain higher total payment for real cures and a strong incentive to select patients well and improve durability. Needs a registry to adjudicate outcomes and accounting rules that let payers commit across years.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Incentives reward me-too drugs and marginal gains): Upadhaya et al., PD1/PDL1 inhibitor clinical trial landscape (Nat Rev Drug Discov 2022)","url":"https://doi.org/10.1038/d41573-022-00030-4"}],"tags":[],"related":["idea-fund-public-car-t-manufacturing","idea-fund-mcbs-linked-pricing"],"cancers":["dlbcl","multiple-myeloma"],"sections":[],"technologies":["car-t","mrd-testing"],"targets":[],"drugs":["axicabtagene-ciloleucel","ciltacabtagene-autoleucel"],"companies":[],"institutions":[],"pathways":[],"terms":["mrd","real-world-evidence"],"trials":[],"people":[],"bottlenecks":["b-incentive-misalignment","b-drug-pricing"],"keyPapers":["paper-upadhaya-nat-rev-drug-discov"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Annuity contracts for CAR-T in lymphoma and myeloma lower payer cost per durable remission by at least 20% compared with up-front pricing, without reducing patient access, and manufacturers increase investment in durability (consolidation, MRD-guided retreatment) measurably.","rationale":"Contracts exist for Zolgensma and haemophilia gene therapies in several countries; oncology has cleaner outcome definitions (relapse) than many indications. Paying for outcomes corrects the current system where a therapy that fails at month six costs the same as one that cures.","test":"A national payer pilots annuity contracts for CAR-T in one indication with a registry-based remission adjudication, comparing cost per remission-year and access metrics against a control region with up-front pricing.","maturity":"early-clinical","actor":"payer","cost":"medium","horizonYears":4},"route":"/ideas/idea-fund-pay-for-cure-annuities/","neighbours":{"idea":[{"id":"idea-fund-public-car-t-manufacturing","kind":"idea","name":"Hospital-based CAR-T manufacturing at cost through a public network","route":"/ideas/idea-fund-public-car-t-manufacturing/"},{"id":"idea-fund-mcbs-linked-pricing","kind":"idea","name":"Launch prices indexed to the ESMO benefit scale, revisited when survival matures","route":"/ideas/idea-fund-mcbs-linked-pricing/"}],"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"axicabtagene-ciloleucel","kind":"drug","name":"Axicabtagene ciloleucel","route":"/drugs/axicabtagene-ciloleucel/"},{"id":"ciltacabtagene-autoleucel","kind":"drug","name":"Ciltacabtagene autoleucel","route":"/drugs/ciltacabtagene-autoleucel/"}],"term":[{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"},{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"}],"paper":[{"id":"paper-upadhaya-nat-rev-drug-discov","kind":"paper","name":"Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape","route":"/key-papers/paper-upadhaya-nat-rev-drug-discov/"}]}}